Adult female acne is a notoriously stubborn, frustrating condition. Unlike the acne experienced during teenage years, which is often characterized by widespread comedones (blackheads and whiteheads) across the forehead and cheeks, adult female acne typically presents as deep, tender, painful nodules and papules concentrated along the jawline, chin, and lower third of the face. These flares are frequently cyclical, worsening in the days leading up to a menstrual period, and are often highly resistant to standard first-line topical treatments, salicylic acid peels, and oral antibiotics like doxycycline.

For patients looking for a direct answer: Spironolactone is an effective, evidence-backed off-label oral treatment for adult female hormonal acne. It is not FDA-approved for acne but is conditionally recommended by the American Academy of Dermatology (AAD), typically dosed at 50 to 200 mg daily with visible results appearing at 3 to 6 months. While it carries an FDA boxed warning for cancer, large human studies (including a Danish cohort of roughly 2.3 million women) show no association with breast cancer. Furthermore, clinical trials show that hyperkalemia (high blood potassium) is extremely rare in young, healthy women, meaning routine potassium blood tests are generally unnecessary for healthy patients under 45. Spironolactone is strictly contraindicated in pregnancy due to the risk of feminizing a male fetus, and it is not prescribed to men for acne due to the risk of gynecomastia.

To understand whether spironolactone is the right option for your skin, it is necessary to examine how the drug works, the clinical evidence supporting its use, typical dosing titration strategies, potential side effects, and how it compares to alternative systemic therapies on the oral anti-androgen rung of the acne evidence ladder.

What Is Spironolactone and How Does It Clear Hormonal Acne?

Spironolactone was not originally developed as a dermatology drug. First synthesized and approved by the FDA in 1960 under the brand name Aldactone (NDA 012151, originally developed by G.D. Searle & Co., now a subsidiary of Pfizer), spironolactone is classified as a potassium-sparing diuretic and selective aldosterone receptor antagonist. For decades, its primary clinical indications have centered on cardiovascular and renal medicine: managing edema (fluid retention) associated with congestive heart failure, hepatic cirrhosis, and nephrotic syndrome, as well as treating essential hypertension and primary hyperaldosteronism.

However, spironolactone possesses a secondary pharmacological mechanism that makes it highly effective in dermatology: it acts as a weak systemic anti-androgen.

Androgen Hormones (e.g., Testosterone, DHT)
         │
         ▼ (Bind to Androgen Receptors in Sebaceous Glands)
Stimulate Sebum (Oil) Production
         │
         ▼ (Clogs Pores + Promotes Bacterial Growth)
Inflammatory Acne Vulgaris (Lower Face / Jawline)

=======================================================

Spironolactone Intervention:
1. Competitively blocks Androgen Receptors in the skin.
2. Inhibits 5-alpha reductase (blocks Conversion of Testosterone to DHT).
3. Decreases Sebum Production at the source.

In female patients, sebum production is heavily regulated by circulating androgens (such as testosterone and dihydrotestosterone, or DHT), even when blood tests show hormone levels are within the normal range. The sebaceous (oil-producing) glands in the skin contain androgen receptors. When androgens bind to these receptors, they stimulate the glands to produce excess sebum. This excess oil clogs pores, creates an anaerobic environment that promotes the overgrowth of Cutibacterium acnes bacteria, and triggers the inflammatory cascade that results in deep, cystic acne.

Spironolactone clears acne by interrupting this pathway in two distinct ways:

Competitive Receptor Inhibition: It binds directly to androgen receptors in the sebaceous glands, preventing circulating testosterone and DHT from binding and signaling the glands to produce oil.
Enzyme Inhibition: It decreases the activity of 5-alpha reductase, the intracellular enzyme responsible for converting weak testosterone into the far more potent androgen DHT, and increases the synthesis of sex hormone-binding globulin (SHBG) in the liver, which binds up free testosterone in the bloodstream so it cannot act on the skin.

By lowering sebum excretion, spironolactone addresses the root cause of hormonal flares. This anti-androgenic effect is also the reason why spironolactone is also discussed for hair loss (female pattern hair loss or androgenetic alopecia), where it helps prevent DHT-induced hair follicle miniaturization on the scalp.

Is Spironolactone FDA-Approved for Acne, and What Does Off-Label Mean Here?

A common source of confusion for patients is the drug’s regulatory status. Spironolactone is not FDA-approved for the treatment of acne vulgaris.

In the United States, when a pharmaceutical company seeks FDA approval for a drug, it must fund and conduct massive, multi-million-dollar phase-3 randomized controlled clinical trials demonstrating the drug's safety and efficacy for a specific disease or indication. Once approved, the drug's official prescribing information (the label) lists that indication.

Because spironolactone is a generic, inexpensive drug that has been available since 1960, no pharmaceutical manufacturer has a financial incentive to fund the costly clinical trials required to officially update the FDA label to include acne. As a result, when a dermatologist writes a prescription for spironolactone to treat acne, they are practicing what is known as off-label prescribing.

Off-label prescribing is entirely legal, common, and considered a standard part of modern medical practice. According to the Agency for Healthcare Research and Quality (AHRQ), roughly one in five prescriptions written in the United States is for an off-label use. In dermatology, many mainstay treatments—including spironolactone for acne, oral tranexamic acid for melasma, and oral beta-blockers for infantile hemangiomas—are prescribed off-label because their clinical efficacy is widely established by independent researchers and medical societies, even if the official FDA label has not been updated.

The clinical legitimacy of spironolactone for acne is reflected in major professional guidelines. The American Academy of Dermatology's Guidelines of Care for the Management of Acne Vulgaris conditionally recommends oral spironolactone as a safe and effective systemic option for the management of inflammatory acne in adult females.

What Dose Do Dermatologists Use and How Long Until It Works?

Because spironolactone is prescribed off-label for acne, the dosing protocol differs significantly from its use in cardiovascular medicine. In heart failure or hypertension, doses can range from 25 mg to over 200 mg daily, often requiring close monitoring of kidney function and electrolytes due to the patients' underlying cardiovascular illness.

For acne, dermatologists typically prescribe spironolactone within a range of 50 mg to 200 mg daily.

50 mg/day: Often used as a starting dose for patients who are sensitive to medications or have lower baseline blood pressure. While some patients achieve clear skin at 50 mg, clinical reviews suggest it is less effective as monotherapy and is more commonly used as a starting point to assess tolerability before titration.
100 mg/day: The standard, most common therapeutic dose for acne. Clinical trials show that 100 mg daily strikes the optimal balance between clearing inflammatory acne lesions and minimizing systemic side effects. Most dermatologists recommend starting at or titrating up to this dose.
150 mg to 200 mg/day: Reserved for patients with severe, treatment-resistant hormonal acne who tolerate 100 mg daily but do not achieve complete clearance. Doses above 100 mg are associated with a higher frequency of dose-dependent side effects, such as menstrual irregularities.

Titration and Dosing Schedules

To minimize side effects like dizziness or frequent urination, many dermatologists utilize a titration schedule:

Week	Daily Dose	Scheduling	Clinical Goal
Weeks 1 – 2	50 mg	Take once daily (morning or night) with food	Assess initial tolerability, blood pressure adjustments
Week 3 onward	100 mg	Take 100 mg once daily, or split into 50 mg twice daily	Active therapeutic phase for hormone receptor blockade
Month 3 evaluation	100 – 150 mg	Adjust based on inflammatory lesion count and side effects	Titrate up only if acne persists and side effects are minimal

Taking spironolactone with food is highly recommended, as lipid-rich meals significantly increase the drug's bioavailability and absorption. Additionally, taking the medication in the morning or early afternoon is preferred to prevent nocturia (waking up in the middle of the night to urinate).

The Efficacy Timeline: Managing Expectations

Unlike oral antibiotics, which can reduce inflammatory acne within a few weeks by killing bacteria directly, spironolactone requires a patient timeline. It takes time for the systemic anti-androgen effect to lower sebum production, clear existing clogged pores, and prevent new lesions from forming.

Patients must be prepared for the following timeline:

Weeks 1 – 4: No noticeable improvement in acne. Some patients may experience mild, transient side effects (e.g., increased urination or mild dizziness) as their body adjusts.
Weeks 4 – 8: A gradual reduction in the severity and frequency of deep cystic flares along the jawline. Active breakouts heal faster.
Month 3 (12 Weeks): The typical milestone for initial meaningful clinical response. Most patients see a significant drop in active lesions.
Month 6 (24 Weeks): Peak efficacy. Skin is typically clear or near-clear, and the focus shifts to maintaining results and addressing residual post-inflammatory hyperpigmentation.

Because of this gradual onset, dermatologists advise patients to commit to at least a 3-to-6-month trial before deciding whether the medication is working. Once clearance is achieved, spironolactone can be taken safely for years as maintenance therapy, provided the patient does not plan to become pregnant.

Clinical Efficacy: What the SAFA Phase-3 Trial Proves

For decades, the clinical support for spironolactone in acne was built on retrospective cohort studies, open-label trials, and smaller institutional reviews. While these studies consistently showed high rates of patient satisfaction, the lack of a large-scale, double-blind, randomized controlled trial (RCT) prevented spironolactone from achieving a strong recommendation in medical guidelines.

This gap was closed in 2023 with the publication of the SAFA (Spironolactone for Adult Female Acne) trial in The BMJ. The SAFA study was a pragmatic, multicenter, phase-3, double-blind, randomized, placebo-controlled trial conducted across primary and secondary care dermatology sites in England and Wales.

The trial enrolled 410 adult women (aged 18 and older) with persistent, inflammatory acne vulgaris of at least six months' duration that was deemed severe enough to warrant systemic therapy. Participants were randomized in a 1:1 ratio to receive either oral spironolactone (dosed at 50 mg/day titrating to 100 mg/day at week 6) or a matching placebo for 24 weeks.

The results of the SAFA trial provided definitive, high-quality evidence of spironolactone's efficacy:

Primary Outcome — Acne-QoL at Week 12: The trial's pre-specified primary endpoint was the Acne-Specific Quality of Life (Acne-QoL) symptom subscale score at week 12. The spironolactone group improved significantly more than placebo (adjusted mean difference 1.27 points, 95% confidence interval 0.07–2.46), and the benefit grew larger by week 24 (difference 3.45, 95% CI 2.16–4.75).
Participant-Reported Improvement (Week 24): By the end of the 24-week treatment period, 82% of women in the spironolactone group reported that their acne had improved, compared to 63% in the placebo group (a statistically significant difference). Notably, at week 12 the gap was not yet significant (72% vs. 68%), so the clearest patient-perceived benefit appears later in treatment.
Investigator's Global Assessment (IGA): Investigator-assessed treatment success (defined as clear or almost clear skin with a 2-grade improvement on the IGA scale) was achieved by 19% of the spironolactone group at week 12, compared with just 6% of the placebo group.
Adverse Events: Side effects were slightly more common in the spironolactone group — most often headache and lightheadedness — but were overwhelmingly mild and transient. Importantly, there were zero serious adverse reactions attributed to spironolactone during the trial.

The SAFA trial confirmed that spironolactone is a highly effective systemic alternative to long-term oral antibiotics, allowing providers to achieve clear skin in female patients while practicing proper antibiotic stewardship.

Side Effects: Periods, Blood Pressure, Potassium, and the Cancer Warning Explained

Like any systemic medication, spironolactone carries a risk of side effects. However, because it is prescribed for acne in a young, healthy female population at lower doses than those used in cardiology, the real-world side effect profile is highly favorable. Understanding the distinction between common mild side effects, the potassium-monitoring debate, and the FDA boxed warning is critical for patient reassurance.

Common, Dose-Dependent Side Effects

Because spironolactone blocks androgen receptors and acts as a mild diuretic, patients may experience:

Menstrual Irregularities: Among the most common side effects, reported in roughly 15–30% of patients (about 22% in the largest long-term survey) and highly dose-dependent — uncommon at 50 mg, more frequent at 100 mg, and common at 150–200 mg. Because spironolactone affects progesterone and androgen pathways, it can cause irregular periods, spotting between cycles (metrorrhagia), or shorter cycles (polymenorrhea). It is usually resolved by pairing spironolactone with a combined oral contraceptive pill.
Breast Tenderness or Enlargement: Androgen blockade can lead to relative estrogen dominance, causing mild breast tenderness or swelling. This is typically transient and resolves with continued use or dose reduction.
Polyuria (Frequent Urination) and Polydipsia (Increased Thirst): As a mild diuretic, spironolactone increases the excretion of water and sodium. Patients should expect to urinate more frequently, especially during the first few weeks, and should increase their daily water intake.
Orthostatic Hypotension and Dizziness: A slight lowering of blood pressure can cause a temporary feeling of lightheadedness or dizziness, particularly when standing up quickly. Taking the medication with food and staying hydrated mitigates this.
Fatigue and Headache: Some patients report mild lethargy or headaches when initiating therapy, which usually resolve within the first month.

The Potassium-Monitoring Debate: What the Data Shows

For many years, the official FDA label for Aldactone mandated routine blood tests to monitor serum potassium levels due to the risk of hyperkalemia (elevated blood potassium). Because spironolactone blocks aldosterone, the kidneys retain potassium while excreting sodium. In patients with kidney failure or heart disease, hyperkalemia is a dangerous risk that can cause cardiac arrhythmias.

However, in the context of treating acne in healthy young women, clinical research has proven that routine potassium monitoring is low-yield and unnecessary.

A landmark study published in JAMA Dermatology in 2015 by Plovanich et al. reviewed the laboratory results of 974 healthy young women taking spironolactone for acne.

Potassium Level Measurements in 974 Healthy Young Women:
Total Measurements: 1,802
Hyperkalemia (Potassium > 5.0 mEq/L) Rate: 0.72% (13 measurements)
Baseline Rate (Untreated Women): 0.76%
============================================================
Conclusion: The rate of high potassium in women taking spironolactone 
is identical to the normal background rate. Routine monitoring is low-yield.

The study analyzed 1,802 serum potassium measurements. The researchers found:

The hyperkalemia rate among women taking spironolactone was 0.72% (13 measurements).
The baseline rate of hyperkalemia in healthy, untreated young women was 0.76%.
All observed cases of hyperkalemia were mild, asymptomatic, and resolved upon repeat testing without requiring drug discontinuation.

Based on this data, the authors concluded that routine potassium monitoring is unnecessary for healthy young women with normal kidney function taking typical acne doses (≤100 mg/day). This consensus has been widely adopted by dermatologists.

However, potassium monitoring is still recommended for:

Women over the age of 45 (as renal function naturally declines and the risk of hyperkalemia rises).
Patients with known renal impairment, chronic kidney disease, or cardiac disorders.
Patients concurrently taking other medications that increase potassium levels, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or high-dose nonsteroidal anti-inflammatory drugs (NSAIDs). The FDA's 2022 label revision (S-079) explicitly highlighted these drug-drug interactions.

The FDA Boxed Warning: Rodent Data vs. Human Reality

Every box of brand-name Aldactone or generic spironolactone carries a prominent, black-bordered warning stating that the drug has been shown to be a tumorigen in chronic toxicity studies in rats, warning against its unnecessary use. This boxed warning frequently alarms patients.

To understand the warning, one must look at the toxicology study design:

The Rodent Studies: The warning is based on studies in which rats were fed spironolactone daily for up to two years. The doses administered were 25 to 250 times the human equivalent dose based on body weight. At these massive, toxic levels, the rats showed an increased incidence of benign thyroid follicular adenomas and testicular interstitial cell tumors, as well as proliferative liver changes.
The Human Evidence: In the 60+ years that spironolactone has been prescribed to millions of patients worldwide, extensive epidemiological data has failed to show a statistically significant link between spironolactone and cancer in humans.

Specifically, a nationwide Danish cohort study published in Cancer Epidemiology in 2013 by Biggar and colleagues followed roughly 2.3 million women (28.5 million person-years) and found no evidence of an increased risk of breast cancer — or uterine, ovarian, or cervical cancer — among women who used spironolactone.

Furthermore, an 8-year long-term safety survey of 91 women taking spironolactone for acne (representing 200 person-years of drug exposure and 506 person-years of follow-up) published in the Journal of Cutaneous Medicine and Surgery found no serious adverse events or malignancies attributable to the drug.

Dermatologists routinely discuss this data with patients, explaining that the boxed warning represents a regulatory requirement based on high-dose animal models that have not translated into a real-world cancer risk for humans.

Who Should Not Take Spironolactone?

While spironolactone is highly safe for the vast majority of female acne patients, there are absolute contraindications and patient populations who must avoid it.

1. Pregnancy and Breastfeeding (Absolute Contraindication)

Spironolactone is strictly contraindicated during pregnancy. Because of its anti-androgenic mechanism, if a pregnant woman takes spironolactone while carrying a male fetus, the drug can block the androgen receptors necessary for normal male reproductive tract development. This can result in the feminization of the male fetus (undescended testicles, hypospadias).

Historically classified under FDA Pregnancy Category X, spironolactone requires that women of childbearing potential use reliable contraception while taking the drug. This is why dermatologists frequently co-prescribe spironolactone with combined oral contraceptives, which serve the dual purpose of preventing pregnancy and controlling menstrual irregularities. If a patient decides they want to conceive, they must discontinue spironolactone at least one week prior to stopping contraception to allow the drug and its active metabolites (such as canrenone) to clear from their system.

Regarding lactation, the active metabolites of spironolactone are excreted in breast milk in extremely low quantities (less than 1% of the maternal dose). While generally considered compatible with breastfeeding by the American Academy of Pediatrics, most dermatologists recommend withholding systemic anti-androgens during early postpartum lactation until breastfeeding is established.

2. Male Patients

Spironolactone is not prescribed for acne in male patients.

Because men rely on circulating androgens for muscle mass, libido, erectile function, and secondary male characteristics, blocking these receptors systemically leads to severe, unacceptable side effects. In men, spironolactone causes:

Gynecomastia: The development of glandular breast tissue.
Loss of Libido and Erectile Dysfunction: Due to systemic testosterone blockade.
Muscle Weakness and Fatigue: As a result of lowered androgen activity.
Testicular Atrophy: Over long-term use.

For male patients with stubborn acne, dermatologists instead utilize topical retinoids, benzoyl peroxide, oral antibiotics, or oral isotretinoin.

3. Severe Renal or Hepatic Impairment

Because spironolactone and its metabolites are cleared primarily by the kidneys and metabolized in the liver, patients with acute renal failure, significant chronic kidney disease (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73m²), or severe liver disease are at a high risk of developing severe hyperkalemia and fluid-electrolyte imbalances.

How Spironolactone Compares to Alternative Acne Therapies

Choosing the right systemic acne therapy involves comparing spironolactone against other common options, such as oral contraceptives, oral isotretinoin, and topical anti-androgens.

Spironolactone vs. Combined Oral Contraceptives (COCs)

Oral contraceptive pills clear acne by suppressing ovarian androgen production and increasing SHBG. The FDA has approved four combined oral contraceptives for acne — Ortho Tri-Cyclen (norgestimate), Estrostep (norethindrone acetate), and Yaz and Beyaz (both drospirenone), all paired with ethinyl estradiol.

Mechanism: COCs lower overall hormone production; spironolactone blocks hormone receptors.
Efficacy: Both are highly effective for hormonal acne. Studies suggest spironolactone achieves slightly higher rates of complete clearance, particularly along the jawline.
Tradeoffs: COCs carry a small risk of blood clots (thromboembolism), which is higher than the risk associated with spironolactone. However, COCs regulate menstrual cycles, whereas spironolactone can cause spotting.
Clinical Practice: Dermatologists frequently combine them. Stacking spironolactone with a combined birth control pill (especially one containing drospirenone, a spironolactone-derived progestin) provides a synergistic effect, clearing skin faster while ensuring contraception and regular periods.

Spironolactone vs. Isotretinoin (Accutane)

Isotretinoin is an oral vitamin A derivative that temporarily shuts down sebaceous gland activity. It is the only treatment that can cure acne permanently.

Efficacy: Isotretinoin is more potent than spironolactone and is the gold standard for severe, scarring, nodulocystic acne. Spironolactone is highly effective but is a suppressive therapy—when a patient stops taking spironolactone, their hormonal acne will typically return.
Safety and Monitoring: Isotretinoin requires participation in the strict FDA iPLEDGE REMS program, monthly pregnancy tests, and regular liver function/lipid blood tests. Spironolactone has no registry requirements and requires no routine lab work for healthy young women.
Side Effects: Isotretinoin causes severe dryness of the lips, skin, and eyes, and carries risks of bone pain, night blindness, and potential mood changes. Spironolactone side effects are far milder.
Candidacy: For an adult woman with moderate, cyclical, lower-face acne, spironolactone is often preferred as a first-line systemic agent to avoid the side effects and lifestyle restrictions of a 6-month Accutane course. However, for severe scarring acne, spironolactone versus isotretinoin for hormonal acne tilts heavily toward isotretinoin to prevent permanent structural skin damage.

Spironolactone vs. Topical Clascoterone (Winlevi)

Approved by the FDA in 2020, clascoterone 1% cream is the first topical androgen receptor inhibitor.

Mechanism: Clascoterone competes with DHT directly at the androgen receptors within the skin, without systemic absorption.
Efficacy: While effective for mild-to-moderate hormonal acne, topical clascoterone does not match the clinical clearing power of oral spironolactone for deep, systemic cystic nodules.
Tradeoffs: Winlevi is safe for both male and female patients and carries no systemic side effects. However, it requires twice-daily application and can be highly expensive depending on insurance coverage. It is often prescribed as a topical add-on for patients who cannot tolerate or choose not to take oral spironolactone.

Practical Skincare Stacking: Retinoids and Spironolactone

Systemic therapy works best when paired with a supportive topical routine. Because spironolactone targets sebum production from the inside out, it should be paired with topical agents that address pore clogging and skin cell turnover from the outside.

The classic clinical combination is stacking spironolactone with a topical retinoid.

The Rationale: While spironolactone dries up excess oil, a prescription topical retinoid—such as tretinoin 0.05% cream or tazarotene 0.045% lotion—works to accelerate cellular exfoliation, clearing out existing microcomedones and preventing new clogs. This synergistic approach clears active lesions faster. To determine which topical retinoid fits your skin barrier, read the retinol vs tretinoin comparison.
skincare Routine Adjustments: Because spironolactone can make the skin slightly drier, patients should simplify their topical routine to prevent skin-barrier disruption. Avoid over-cleansing and limit the use of harsh exfoliants like salicylic acid or glycolic acid in the first weeks of starting a retinoid-spironolactone stack. Focus on a gentle cleanser, a ceramide-rich moisturizer, and a mineral sunscreen.

For patients experiencing hormonal acne later in life, particularly during the transition to menopause, spironolactone remains a key tool. In these cases, it is often prescribed to manage the sudden androgen flares that occur as estrogen levels drop. For a detailed guide on managing these hormonal skin shifts, refer to the reference on spironolactone for perimenopausal jawline acne.

FAQs

Is spironolactone FDA-approved for acne?

No, spironolactone is not FDA-approved for the treatment of acne. It is FDA-approved as a diuretic and antihypertensive medication. Prescribing it for acne is considered an "off-label" medical practice, which is fully legal and is a widely accepted clinical practice recommended by the American Academy of Dermatology.

How long does spironolactone take to work on acne?

Spironolactone is a slow-acting medication. Most patients begin to see a reduction in active breakouts after 4 to 8 weeks, with initial meaningful clearance appearing at 3 months (12 weeks). Peak clinical results and complete skin clearing typically occur around 6 months (24 weeks).

Does spironolactone cause breast cancer?

No. While spironolactone carries an FDA boxed warning regarding tumors in rodents, large-scale human data has found no association between spironolactone use and breast cancer. A nationwide Danish cohort of roughly 2.3 million women found no increased risk of breast cancer (or uterine, ovarian, or cervical cancer) with spironolactone use.

Do I need my potassium checked while on spironolactone for acne?

If you are a healthy woman under the age of 45 with normal kidney function, you do not need routine potassium blood tests. Large studies have shown the rate of hyperkalemia in this population is identical to the untreated background rate (0.72% vs. 0.76%). Potassium monitoring is still recommended for patients over 45, those with kidney disease, or those taking interacting blood pressure medications like ACE inhibitors or ARBs.

Can men take spironolactone for acne?

No. Spironolactone is not prescribed for acne in male patients. Due to its systemic androgen-blocking mechanism, it causes severe side effects in men, including gynecomastia (breast tissue development), erectile dysfunction, loss of libido, and muscle weakness.

Is spironolactone safe in pregnancy or while trying to conceive?

No. Spironolactone is strictly contraindicated during pregnancy because it can disrupt the normal reproductive development of a male fetus, leading to feminization. Women of childbearing age must use reliable contraception while taking it. If you plan to try to conceive, you must stop taking spironolactone at least one week prior to discontinuing birth control.

Sources

Biggar, R. J., Andersen, E. W., Wohlfahrt, J., & Melbye, M. (2013). Spironolactone use and the risk of breast and gynecologic cancers. Cancer Epidemiology, 37(6), 870–875. https://doi.org/10.1016/j.canep.2013.10.004
Plovanich, M., Weng, Q. Y., & Mostaghimi, A. (2015). Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne. JAMA Dermatology, 151(9), 941–944. https://doi.org/10.1001/jamadermatol.2015.34
Santer, M., et al. (2023). Effectiveness of spironolactone for women with acne vulgaris (SAFA): pragmatic multicentre phase 3 double-blind randomised controlled trial. The BMJ, 381, e074349. https://doi.org/10.1136/bmj-2022-074349
U.S. Food and Drug Administration. (2022). Aldactone (spironolactone) tablets prescribing information, NDA 012151, S-079 (2022 revision). Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/012151s079lbl.pdf
Reynolds, R. V., et al. (2024). Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology, 90(5), 1006.e1–1006.e30. https://doi.org/10.1016/j.jaad.2023.12.017
Shaw, J. C., & White, L. E. (2002). Long-term safety of spironolactone in acne: results of an 8-year follow-up study. Journal of Cutaneous Medicine and Surgery, 6(6), 541–545. https://doi.org/10.1007/s10227-001-0152-4
National Library of Medicine (DailyMed). (2023). Spironolactone tablet prescribing information. Retrieved from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29b8c04f-7f7f-4428-8686-2a7e442828b8

Spironolactone for Hormonal Acne: Off-Label Use, Dosing, Side Effects, and Cancer Risk